间变性甲状腺癌的管理
Management of anaplastic thyroid cancer.
作者信息
Keutgen Xavier M, Sadowski Samira M, Kebebew Electron
机构信息
Endocrine Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda 20892, Maryland, USA.
出版信息
Gland Surg. 2015 Feb;4(1):44-51. doi: 10.3978/j.issn.2227-684X.2014.12.02.
Abstract
Anaplastic thyroid cancer (ATC) is a deadly disease with a dismal prognosis. Molecular analyses of ATC tumors have yielded interesting results, which could help in understanding the underlying mechanisms of this aggressive disease process. Managing ATC can be challenging and includes rapid diagnosis, adequate staging, and interdisciplinary, multimodal treatments to optimize patient outcome. Treatments include surgical resection to gross negative margins when possible, as well as neo- or adjuvant treatment with chemotherapy or external beam radiation (XRT) for locoregional disease. New treatment strategies include evaluating the benefits of vascular disrupting agents and tyrosine kinase inhibitors for advanced ATC with driver mutations, which can be targeted. This review summarizes key concepts in managing ATC.
摘要
间变性甲状腺癌（ATC）是一种预后极差的致命疾病。对ATC肿瘤的分子分析已得出有趣的结果，这有助于理解这种侵袭性疾病过程的潜在机制。管理ATC具有挑战性，包括快速诊断、充分分期以及采用多学科、多模式治疗以优化患者预后。治疗方法包括尽可能进行手术切除至切缘阴性，以及对局部区域性疾病采用化疗或外照射放疗（XRT）进行新辅助或辅助治疗。新的治疗策略包括评估血管破坏剂和酪氨酸激酶抑制剂对具有可靶向驱动突变的晚期ATC的益处。本综述总结了管理ATC的关键概念。
相似文献
1
Management of anaplastic thyroid cancer.间变性甲状腺癌的管理
Gland Surg. 2015 Feb;4(1):44-51. doi: 10.3978/j.issn.2227-684X.2014.12.02.
2
Anaplastic thyroid cancer: prevalence, diagnosis and treatment.间变性甲状腺癌：患病率、诊断与治疗
Minerva Endocrinol. 2008 Dec;33(4):341-57.
3
Novel treatments for anaplastic thyroid carcinoma.间变性甲状腺癌的新型治疗方法。
Gland Surg. 2020 Jan;9(Suppl 1):S28-S42. doi: 10.21037/gs.2019.10.18.
4
Spanish consensus for the management of patients with anaplastic cell thyroid carcinoma.西班牙间变性细胞甲状腺癌患者管理共识
Endocrinol Nutr. 2015 Mar;62(3):e15-22. doi: 10.1016/j.endonu.2014.11.006. Epub 2015 Jan 9.
5
Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches.间变性甲状腺癌：生物学、发病机制、预后因素及治疗方法
Ann Surg Oncol. 2006 Apr;13(4):453-64. doi: 10.1245/ASO.2006.05.042. Epub 2006 Feb 15.
6
DURABLE RESPONSE IN A CASE OF METASTATIC ANAPLASTIC THYROID CANCER USING A COMBINATION OF TYROSINE KINASE INHIBITORS AND A CHECK POINT INHIBITOR.酪氨酸激酶抑制剂与检查点抑制剂联合治疗转移性间变性甲状腺癌的持久反应
Acta Endocrinol (Buchar). 2020 Apr-Jun;16(2):236-241. doi: 10.4183/aeb.2020.236.
7
Antineoplastic Effect of Lenvatinib and Vandetanib in Primary Anaplastic Thyroid Cancer Cells Obtained From Biopsy or Fine Needle Aspiration.乐伐替尼和凡德他尼对取自活检或细针穿刺的原发性间变性甲状腺癌细胞的抗肿瘤作用
Front Endocrinol (Lausanne). 2018 Dec 18;9:764. doi: 10.3389/fendo.2018.00764. eCollection 2018.
8
Anaplastic thyroid carcinoma.间变性甲状腺癌。
Front Endocrinol (Lausanne). 2012 Jul 5;3:84. doi: 10.3389/fendo.2012.00084. eCollection 2012.
9
Changes of Clinicopathologic Characteristics and Survival Outcomes of Anaplastic and Poorly Differentiated Thyroid Carcinoma.间变性和低分化甲状腺癌的临床病理特征变化及生存结局。
Thyroid. 2016 Mar;26(3):404-13. doi: 10.1089/thy.2015.0316. Epub 2015 Dec 14.
10
Anaplastic thyroid carcinoma: clinical outcome of 30 consecutive patients referred to a single institution in the past 5 years.间变性甲状腺癌：过去5年转诊至单一机构的30例连续患者的临床结局。
Eur J Endocrinol. 2007 Apr;156(4):425-30. doi: 10.1530/EJE-06-0677.
引用本文的文献
1
Decisive role of surgery on improving overall survival outcomes of primary thyroid sarcoma: the first long-term cohort study.手术对改善原发性甲状腺肉瘤总体生存结局的决定性作用：首项长期队列研究
Endocrine. 2025 Jun 5. doi: 10.1007/s12020-025-04281-0.
2
The Potential Therapeutic Value of Aspirin in Anaplastic Thyroid Cancer.阿司匹林在间变性甲状腺癌中的潜在治疗价值。
Cancers (Basel). 2024 Dec 17;16(24):4203. doi: 10.3390/cancers16244203.
3
RAS-RAF-miR-296-3p signaling axis increases Rad18 expression to augment radioresistance in pancreatic and thyroid cancers.RAS-RAF-miR-296-3p 信号轴增加 Rad18 表达，增强胰腺和甲状腺癌细胞的放射抵抗性。
Cancer Lett. 2024 Jun 1;591:216873. doi: 10.1016/j.canlet.2024.216873. Epub 2024 Apr 10.
4
Emergency Tracheostomy in Locally Advanced Anaplastic Thyroid Cancer.局部晚期间变性甲状腺癌的急诊气管切开术
Indian J Surg Oncol. 2023 Sep;14(3):714-722. doi: 10.1007/s13193-023-01753-5. Epub 2023 Apr 26.
5
Adding pieces to the puzzle of differentiated-to-anaplastic thyroid cancer evolution: the oncogene E2F7.为甲状腺癌分化-间变演进拼图添砖加瓦：原癌基因 E2F7。
Cell Death Dis. 2023 Feb 10;14(2):99. doi: 10.1038/s41419-023-05603-8.
6
Prognosis of Anaplastic Thyroid Cancer with Distant Metastasis.伴远处转移的间变性甲状腺癌的预后
Cancers (Basel). 2022 Nov 24;14(23):5784. doi: 10.3390/cancers14235784.
7
Expression of T-cell immunoreceptor with immunoglobulin and tyrosine-based inhibitory motif domains (TIGIT) in anaplastic thyroid carcinoma.T 细胞免疫受体含免疫球蛋白和酪氨酸抑制基序结构域（TIGIT）在间变性甲状腺癌中的表达。
BMC Endocr Disord. 2022 Aug 15;22(1):204. doi: 10.1186/s12902-022-01113-4.
8
Function and Clinical Significance of Circular RNAs in Thyroid Cancer.环状RNA在甲状腺癌中的功能及临床意义
Front Mol Biosci. 2022 Jul 22;9:925389. doi: 10.3389/fmolb.2022.925389. eCollection 2022.
9
In Vitro and In Vivo Effects of the Urokinase Plasminogen Activator Inhibitor WX-340 on Anaplastic Thyroid Cancer Cell Lines.尿激酶型纤溶酶原激活物抑制剂 WX-340 的体外和体内对间变性甲状腺癌细胞系的作用。
Int J Mol Sci. 2022 Mar 28;23(7):3724. doi: 10.3390/ijms23073724.
10
ASPM Promotes the Progression of Anaplastic Thyroid Carcinomas by Regulating the Wnt/-Catenin Signaling Pathway.ASPM通过调节Wnt/β-连环蛋白信号通路促进间变性甲状腺癌的进展。
Int J Endocrinol. 2022 Mar 27;2022:5316102. doi: 10.1155/2022/5316102. eCollection 2022.
本文引用的文献
1
Response and acquired resistance to everolimus in anaplastic thyroid cancer.间变性甲状腺癌对依维莫司的反应及获得性耐药
N Engl J Med. 2014 Oct 9;371(15):1426-33. doi: 10.1056/NEJMoa1403352.
2
Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis.激活BRAF和PIK3CA突变协同促进间变性甲状腺癌发生。
Mol Cancer Res. 2014 Jul;12(7):979-86. doi: 10.1158/1541-7786.MCR-14-0158-T. Epub 2014 Apr 25.
3
Cell cycle deregulation and TP53 and RAS mutations are major events in poorly differentiated and undifferentiated thyroid carcinomas.细胞周期失调以及 TP53 和 RAS 基因突变是低分化和未分化甲状腺癌的主要事件。
J Clin Endocrinol Metab. 2014 Mar;99(3):E497-507. doi: 10.1210/jc.2013-1512. Epub 2014 Jan 13.
4
Marginal treatment benefit in anaplastic thyroid cancer.间变甲状腺癌的治疗效益边际。
Cancer. 2013 Sep 1;119(17):3133-9. doi: 10.1002/cncr.28187. Epub 2013 Jul 9.
5
Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma.随机对照的福司替尼联合紫杉醇/卡铂治疗间变性甲状腺癌的安全性和有效性研究。
Thyroid. 2014 Feb;24(2):232-40. doi: 10.1089/thy.2013.0078. Epub 2013 Sep 10.
6
Redifferentiation and induction of tumor suppressors miR-122 and miR-375 by the PAX8/PPARγ fusion protein inhibits anaplastic thyroid cancer: a novel therapeutic strategy.PAX8/PPARγ 融合蛋白对肿瘤抑制因子 miR-122 和 miR-375 的再分化和诱导抑制间变性甲状腺癌：一种新的治疗策略。
Cancer Gene Ther. 2013 May;20(5):267-75. doi: 10.1038/cgt.2013.16. Epub 2013 Apr 19.
7
Anaplastic thyroid cancer.间变性甲状腺癌。
Oral Oncol. 2013 Jul;49(7):702-6. doi: 10.1016/j.oraloncology.2013.03.440. Epub 2013 Apr 11.
8
BRAF V600E inhibition in anaplastic thyroid cancer.BRAF V600E 抑制在间变性甲状腺癌中的作用
N Engl J Med. 2013 Feb 14;368(7):684-5. doi: 10.1056/NEJMc1215697.
9
Anaplastic thyroid cancer: rare, fatal, and neglected.间变性甲状腺癌：罕见、致命且被忽视。
Surgery. 2012 Dec;152(6):1088-9. doi: 10.1016/j.surg.2012.08.059.
10
Thyroidectomy followed by fosbretabulin (CA4P) combination regimen appears to suggest improvement in patient survival in anaplastic thyroid cancer.甲状腺切除术联合福司氟尿苷（CA4P）方案似乎提示在间变性甲状腺癌患者的生存改善。
Surgery. 2012 Dec;152(6):1078-87. doi: 10.1016/j.surg.2012.08.036.
Zotero 插件